LTRN logo

LANTERN PHARMA INC

LTRNNASDAQ
πŸ† #5028 by market capEarnings Mar 29 Β· PostUS Equity
$0.25β–Ό $0.04 (βˆ’13.73%)
Market closed Β· at close
πŸ””
Track LTRN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 13.7%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$4M
Small Cap
πŸ“ˆRevenue Growth (YoY)
0.0%
Slowing
πŸ“ŠGross Margin
0.0%
Thin
πŸ’΅FCF Margin
0.0%
Thin
βš–οΈP/S Ratio
0.0x
Cheap
Otter Score
β€”
Insufficient data
No chart data available for LTRN.

Trading Snapshot

Day Range
$0.23 – $0.26
52-Week Range
$0.23 – $4.34
Volume (shares)
234,152
Avg Volume (shares)
β€”
Shares Outstanding
14.9M
Next Earnings
2027-03-29

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
-0.2
P/S Ratio
0.0x
EPS (TTM)
$-1.02
Dividend Yield
0.00%
Dilution (1yr)
+1.1%
LTRN logo

LANTERN PHARMA INC

LTRN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$18Mβ–Ό βˆ’19.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$16Mβ–Ό βˆ’12.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
10.9Mβ–² +1.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$4Mβ–Ό βˆ’$3M YoY
StockOtter Β· stockotter.space

About LANTERN PHARMA INC

Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
8 analysts
Strong Buy2
Buy5
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

Business WireΒ·4d ago

Lantern Pharma Reports Third Quarter 2026 Financial Results and Provides Business Updates

DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Third Quarter 2026 Financial Results and Provides Business Updates.

Business WireΒ·12d ago

Lantern Pharma Announces Peer-Reviewed Publication of Phase 1a LP-184 Data in Recurrent Glioblastoma, Supporting a Phase 1b/2a Combination Trial with Spironolactone

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, and its wholly owned subsidiary Starlight Therapeutics today announced the publication of Phase 1a clini

GuruFocusΒ·Oct 7

Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONICβ„’ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received regulatory and IRB approvals in

Business WireΒ·Sep 30

Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering.

Business WireΒ·Sep 29

Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN) (β€œLantern”, the β€œCompany” or β€œwe”), a clinical-stage, AI-native biopharma company using artificial intelligence and genomic data to develop precision oncology t

Seeking AlphaΒ·Sep 23

Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript

Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic Development Transcript